Figure 1
From: A novel anti-IL4Rα nanoparticle efficiently controls lung inflammation during asthma
Proper administration of anti-IL4Rα-NPs to inflamed lung tissue. (a) A diagram representing the synthetized anti-IL4Rα nanoparticles. (b) Histological assessments confirming the targeting of anti-IL4Rα NPs to the inflamed tissue in asthmatic lungs. (i) H&E staining showing tissue inflammation, (ii) Prussian blue staining (marker for iron oxide) showing distribution of SPION within the inflamed tissue and (iii) immunohistochemical staining for PEG using anti-PEG antibodies also confirmed the presence of SPION. The black arrows indicate the localization of the PEGylated nanoparticles. (iv) Immunofluorescence staining showing the presence of the FITC-anti-IL4Rα-NPs within the tissue. Immunofluorescence images were captured at an exposure of 300 ms. Scale bar, 100 μm.
